Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 601–700 of 1,031
Wang, P., Song, Q., Ren, J., Zhang, W., Wang, Y., Zhou, L., Wang, D., Chen, K., Jiang, L., Zhang, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8704 · Cited by 90
Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil
Busque, L., Buscarlet, M., Mollica, L., & Levine, R. L. (2018) · Stem Cells · doi:10.1002/stem.2845 · Cited by 78
Ferrone, C. K., Blydt-Hansen, M., & Rauh, M. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020626 · Cited by 74
“Abbreviations α-KGDDs Alpha-ketoglutarate- and Fe2+-dependent dioxygenases ARCH Age-related clonal hematopoiesis Arg1 Arginase 1 AML Acute myeloid leukemia CCUS Clonal cytopenia of undetermined significance CH Clonal hematopoiesis CHIP Clonal hematopoiesis of indeterminant potential CMML Chronic myelomonocytic leukemi…”
BackgroundInfluentialBellissimo, D. C., Chen, C.-H., Zhu, Q., Bagga, S., Lee, C.-T., He, B., Wertheim, G. B. W., Jordan, M. S., Tan, K., Worthen, G. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000785 · Cited by 83
Whole-genome sequencing analysis of semi-supercentenarians
Garagnani, P., Marquis, J., Delledonne, M., Pirazzini, C., Marasco, E., Kwiatkowska, K. M., Iannuzzi, V., Bacalini, M. G., Valsesia, A., Carayol, J., et al. (2021) · eLife · doi:10.7554/elife.57849 · Cited by 77
New Perspectives on the Importance of Cell-Free DNA Biology
Bronkhorst, A. J., Ungerer, V., Oberhofer, A., Gabriel, S., Polatoglou, E., Randeu, H., Uhlig, C., Pfister, H., Mayer, Z., & Holdenrieder, S. (2022) · Diagnostics · doi:10.3390/diagnostics12092147 · Cited by 83
Self-citationvan Beek, H., Kirkwood, T. B. L., & Bassingthwaighte, J. B. (2016) · Interface Focus · doi:10.1098/rsfs.2015.0079 · Cited by 86
Tarailo-Graovac, M., Zhu, J. Y. A., Matthews, A., van Karnebeek, C. D. M., & Wasserman, W. W. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.50 · Cited by 73
Kwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I. L., Oaknin, A., Aghajanian, C. A., Lorusso, D., Colombo, N., Dean, A. P., Weberpals, J. I., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4664 · Cited by 85
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes
Lees, J. S., Elyan, B. M. P., Herrmann, S. M., Lang, N. N., Jones, R. J., & Mark, P. B. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac011 · Cited by 77
Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes
Ganz, J., Luquette, L. J., Bizzotto, S., Miller, M. B., Zhou, Z., Bohrson, C. L., Jin, H., Tran, A. V., Viswanadham, V., McDonough, G. A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.025 · Cited by 91
Clonal hematopoiesis and atherosclerosis
Oren, O., Small, A. M., & Libby, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180066 · Cited by 82
Application of single-cell genomics in cancer: promise and challenges
Wills, Q. F., & Mead, A. J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv235 · Cited by 74
Yin and Yang: The dual effects of interferons on hematopoiesis
Demerdash, Y., Kain, B., Essers, M. A. G., & King, K. Y. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.02.002 · Cited by 76
“showed that mutations in genes necessary for the replicationdependent histone pre-mRNA-processing complex in patients with Aicardi-Goutiéres syndrome, indicating nuclear histones are also critical in suppressing the immunogenicity of DNA [66].”
BackgroundInfluentialLiquid biopsy tracking of lung tumor evolutions over time
Russo, A., de Miguel‐Pérez, D., Gunasekaran, M., Scilla, K. A., Lapidus, R. S., Cooper, B., Mehra, R., Adamo, V., Malapelle, U., & Rolfo, C. D. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1680287 · Cited by 79
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms
Moliterno, A. R., Ginzburg, Y. Z., & Hoffman, R. (2020) · Blood · doi:10.1182/blood.2020008043 · Cited by 82
Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications
Long, N. A., Golla, U., Sharma, A., & Claxton, D. F. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10308-6 · Cited by 89
“The conditions clonal hematopoiesis of indeterminate potential (CHIP) [24–26] and clonal cytopenias of undetermined significance (CCUS – cytopenias with clonal mutations but no morphological dysplasia) become extremely common with advancing age [23, 24, 27, 28].”
Classification and risk assessment in AML: integrating cytogenetics and molecular profiling
Moarii, M., & Papaemmanuil, E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.37 · Cited by 81
Cargo, C., Cullen, M., Taylor, J., Short, M., Glover, P., Van Hoppe, S., Smith, A., Evans, P., & Crouch, S. (2019) · Blood · doi:10.1182/blood-2018-08-867333 · Cited by 74
Leisch, M., Jansko, B., Zaborsky, N., Greil, R., & Pleyer, L. (2019) · Cancers · doi:10.3390/cancers11020252 · Cited by 82
ATM: Functions of ATM Kinase and Its Relevance to Hereditary Tumors
Ueno, S., Sudo, T., & Hirasawa, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010523 · Cited by 81
“As a result, clones with these variants may expand over time, which is known as clonal hematopoiesis (CH) [83].”
BackgroundMannucci, A., & Goel, A. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02174-w · Cited by 82
Environmental influences on clonal hematopoiesis
King, K. Y., Huang, Y., Nakada, D., & Goodell, M. A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.005 · Cited by 73
“Clonal hematopoiesis (CH) is a condition in which one or a few individual hematopoietic stem cells (HSCs) contribute disproportionately to peripheral blood production (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).”
BackgroundHigh prevalence of focal and multi-focal somatic genetic variants in the human brain
Keogh, M. J., Wei, W., Aryaman, J., Walker, L., van den Ameele, J., Coxhead, J., Wilson, I., Bashton, M., Beck, J., West, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06331-w · Cited by 74
High frequency of clonal hematopoiesis in Erdheim-Chester disease
Aubart, F. C., Roos‐Weil, D., Armand, M., Marceau‐Renaut, A., Emile, J., Duployez, N., Charlotte, F., Poulain, S., Lhote, R., Hélias‐Rodzewicz, Z., et al. (2020) · Blood · doi:10.1182/blood.2020005101 · Cited by 78
Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis
Liao, M., Chen, R., Yang, Y., He, H., Xu, L., Jiang, Y., Guo, Z., He, W., Jiang, H., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.015 · Cited by 67
“Acta Pharmaceutica Sinica B 2022;12(2):678e691”
Chavakis, T., Wielockx, B., & Hajishengallis, G. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-052521-013627 · Cited by 76
A generalized theory of age-dependent carcinogenesis
Rozhok, A., & DeGregori, J. (2019) · eLife · doi:10.7554/elife.39950 · Cited by 73
Scheller, M., Ludwig, A. K., Göllner, S., Rohde, C., Krämer, S., Stäble, S., Janssen, M., Müller, J.-A., He, L., Bäumer, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00213-9 · Cited by 73
The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 mutations
Steinhilber, J., Mederake, M., Bonzheim, I., Serinsöz-Linke, E., Müller, I., Fallier‐Becker, P., Lemonnier, F., Gaulard, P., Fend, F., & Quintanilla‐Martínez, L. (2019) · Modern Pathology · doi:10.1038/s41379-019-0254-4 · Cited by 77
Heritability of skewed X-inactivation in female twins is tissue-specific and associated with age
Zito, A., Davies, M. N., Tsai, P.-C., Roberts, S., Ejarque, R. A., Nardone, S., Bell, J. T., Wong, C. C. Y., & Small, K. S. (2019) · Nature Communications · doi:10.1038/s41467-019-13340-w · Cited by 82
Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals
van Zeventer, I. A., de Graaf, A. O., Wouters, H. J., Van der Reijden, B. A., van der Klauw, M., de Witte, T. M., Jonker, M. A., Malcovati, L., Jansen, J. H., & Huls, G. (2020) · Blood · doi:10.1182/blood.2019004362 · Cited by 73
Márquez, E. J., Trowbridge, J. J., Kuchel, G. A., Banchereau, J., & Ucar, D. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00183-z · Cited by 81
Splicing alterations in healthy aging and disease
Angarola, B. L., & Anczuków, O. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1643 · Cited by 83
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years
Rossi, M., Meggendorfer, M., Zampini, M., Tettamanti, M., Riva, E., Travaglino, E., Bersanelli, M., Mandelli, S., Antonella Galbussera, A., Mosca, E., et al. (2021) · Blood · doi:10.1182/blood.2021011320 · Cited by 70
How, J., Zhou, A. W., & Oh, S. T. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680333 · Cited by 79
“For instance, a significant percentage of MPNassociated mutations, including JAK2 V617F, have been found in elderly individuals without overt evidence of an MPN [Genovese et al. 2014; Xie et al. 2014].”
BackgroundGenomics of Myeloproliferative Neoplasms
Zoi, K., & Cross, N. C. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7968 · Cited by 78
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Micol, J.-B., Pastore, A., Inoue, D., Duployez, N., Kim, E., Lee, S. C.-W., Durham, B. H., Chung, Y. R., Cho, H., Zhang, X. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15429 · Cited by 69
Ganuza, M., Hall, T., Finkelstein, D., Wang, Y.-D., Chabot, A., Kang, G., Bi, W., Wu, G., & McKinney-Freeman, S. (2019) · Blood · doi:10.1182/blood-2018-09-873059 · Cited by 73
Cell‐free tumour DNA testing for early detection of cancer – a potential future tool
Barbany, G., Arthur, C., Liedén, A., Nordenskjöld, M., Rosenquist, R., Tesi, B., Wallander, K., & Tham, E. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12897 · Cited by 89
Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review
Arguelles, O. C., Jaiswal, S., Shlush, L. I., Moslehi, J. J., Schimmer, A. D., Barac, A., & Thavendiranathan, P. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0302 · Cited by 79
Comprehensive Genomic Landscape and Precision Therapeutic Approach in Biliary Tract Cancers
Okamura, R., Kurzrock, R., Mallory, R. J., Fanta, P. T., Burgoyne, A. M., Clary, B. M., Kato, S., & Sicklick, J. K. (2020) · International Journal of Cancer · doi:10.1002/ijc.33230 · Cited by 76
“Also, cases with positive in ctDNA and negative in tissueDNA for certain genes, such as TP53 or KRAS, may be explained by age-related or therapy-related clonal hematopoiesis.(31,32) When stratified according to tissue biopsy sites, ctDNA was numerically more concordant with metastatic site tissue-DNA than primary tumo…”
BackgroundAssessing the Role of Rare Genetic Variation in Patients With Heart Failure
Povysil, G., Chazara, O., Carss, K. J., Deevi, S. V. V., Wang, Q., Armisen, J., Paul, D. S., Granger, C. B., Kjekshus, J., Aggarwal, V., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.6500 · Cited by 73
Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis
Pandey, S. P., Bender, M. J., McPherson, A. C., Phelps, C. M., Sanchez, L. M., Rana, M., Hedden, L., Sangani, K. A., Chen, L., Shapira, J. H., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.05.006 · Cited by 72
Cremers, E. M. P., Westers, T. M., Alhan, C., Cali, C., Visser-Wisselaar, H. A., Chitu, D. A., van der Velden, V. H. J., Marvelde, J. G. T., Klein, S. K., Muus, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.147843 · Cited by 78
De novo Mutations (DNMs) in Autism Spectrum Disorder (ASD): Pathway and Network Analysis
Alonso-González, A., Rodriguez‐Fontenla, C., & Carracedo, Á. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00406 · Cited by 87
“As such, NETBAG has been successfully employed with ASD and schizophrenia data (Gilman et al., 2012).”
BackgroundMethodFei, D. L., Zhen, T., Durham, B. H., Ferrarone, J. R., Zhang, T., Garrett, L. J., Yoshimi, A., Abdel-Wahab, O. I., Bradley, R. K., Liu, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812669115 · Cited by 88
“For example, mutant IDH1 is known to inhibit TET2 enzyme activity (55), and Gata2 and Ikzf1 (as well as Runx1) are transcription factors critical for hematopoietic lineage specification and/or HSC function.”
InfluentialSchrock, A. B., Welsh, A. W., Chung, J., Pavlick, D. C., Bernicker, E., Creelan, B., Forcier, B., Ross, J. S., Stephens, P. J., Ali, S. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.008 · Cited by 75
DNA methylation processes in atherosclerotic plaque
Aavik, E., Babu, M., & Ylä‐Herttuala, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.12.006 · Cited by 83
Karantanos, T., Chaturvedi, S., Braunstein, E. M., Spivak, J. L., Resar, L. M. S., Karanika, S., Williams, D. M., Rogers, O. C., Gocke, C. D., & Moliterno, A. R. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001407 · Cited by 75
Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A., & Ernst, T. (2020) · Cells · doi:10.3390/cells9071639 · Cited by 79
Somatic mutations provide important and unique insights into the biology of complex diseases
Ólafsson, S., & Anderson, C. A. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.06.012 · Cited by 76
Genetics of smoking and risk of clonal hematopoiesis
Levin, M. G., Nakao, T., Zekavat, S. M., Koyama, S., Bick, A. G., Niroula, A., Ebert, B. L., Damrauer, S. M., & Natarajan, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-09604-z · Cited by 75
Longitudinal profiling of clonal hematopoiesis provides insight into clonal dynamics
Uddin, M. M., Zhou, Y., Bick, A. G., Burugula, B. B., Jaiswal, S., Desai, P., Honigberg, M. C., Love, S.-A., Barac, A., Hayden, K. M., et al. (2022) · Immunity & Ageing · doi:10.1186/s12979-022-00278-9 · Cited by 70
“Most studies of CHIP to date rely upon either WGS or WES, or commercial capture kits which have high sequencing or library preparation costs, respectively, ranging from $150–$1000 per sample.”
BackgroundInfluentialGenetics and epidemiology of mutational barcode-defined clonal hematopoiesis
Stacey, S. N., Zink, F., Halldorsson, G. H., Stefansdottir, L., Gudjonsson, S. A., Einarsson, G., Hjörleifsson, G., Eiriksdottir, T., Helgadottir, A., Björnsdottir, G., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01555-z · Cited by 69
“This method enabled us and others to show that CH is very common, if not inevitable, in the elderly 1–3 .”
BackgroundMethodResultMalignant JAK-signaling: at the interface of inflammation and malignant transformation
Perner, F., Pahl, H. L., Zeiser, R., & Heidel, F. H. (2025) · Leukemia · doi:10.1038/s41375-025-02569-8 · Cited by 77
Leveraging Distant Relatedness to Quantify Human Mutation and Gene-Conversion Rates
Palamara, P. F., Francioli, L. C., Wilton, P., Genovese, G., Gusev, A., Finucane, H. K., Sankararaman, S., Sunyaev, S. R., de Bakker, P. I. W., Wakeley, J., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.10.006 · Cited by 80
Self-citationHuang, A. Y., Zhang, Z., Ye, A. Y., Dou, Y., Yan, L., Yang, X., Zhang, Y., & Wei, L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx024 · Cited by 75
“Because the multi-clonal origin of tumor samples was common in many cancer types (16,52), we next employed MosaicHunter to a simulated cancer WGS dataset from ICGC-TCGA DREAM Somatic Mutation Calling Challenge in which the allele fraction of synthetic mutations varied from 20%, 33% to 50% (43).”
MethodConsequences of mutant TET2 on clonality and subclonal hierarchy
Hirsch, C. M., Nazha, A., Kneen, K. E., Abazeed, M. E., Meggendorfer, M., Przychodzen, B. P., Nadarajah, N., Ademà, V., Nagata, Y., Goyal, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0150-9 · Cited by 75
“A higher frequency of CHIP mutations, such as TET2, are seen in people over the age of 60 years old explaining that more ancestral TET2 were found in pAML than sAML likely due to underrepresentation of CBF AML occurring in younger age [34].”
Cakouros, D., & Gronthos, S. (2018) · Aging and Disease · doi:10.14336/ad.2017.1213 · Cited by 73
“In addition, the most frequently mutated genes in hematopoietic cells during aging are epigenetic regulators such as Tet2, DNMT3A and ASXL1 [78, 79].”
BackgroundThe Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly
Pinese, M., Lacaze, P., Rath, E. M., Stone, A., Brion, M.-J., Ameur, A., Nagpal, S., Puttick, C., Husson, S., Degrave, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14079-0 · Cited by 70
Hajishengallis, G., Li, X., Divaris, K., & Chavakis, T. (2022) · Periodontology 2000 · doi:10.1111/prd.12421 · Cited by 76
Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin
Griffin, G. K., Booth, C. A. G., Togami, K., Chung, S. S., Ssozi, D., Verga, J. A., Bouyssou, J., Lee, Y. S., Shanmugam, V., Hornick, J. L., et al. (2023) · Nature · doi:10.1038/s41586-023-06156-8 · Cited by 79
Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs
Hosseini, M., Voisin, V., Chegini, A., Varesi, A., Cathelin, S., Ayyathan, D. M., Liu, A. C. H., Yang, Y., Wang, V. Y., Maher, A., et al. (2025) · Nature · doi:10.1038/s41586-025-08871-w · Cited by 83
Goncalves, I., Burbury, K., Michael, M., Iravani, A., Kumar, A. S. R., Akhurst, T. J., Tiong, I. S., Blombery, P. A., Hofman, M. S., Westerman, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04389-2 · Cited by 71
Towards systematic nomenclature for cell-free DNA
Bronkhorst, A. J., Ungerer, V., Diehl, F., Anker, P., Dor, Y., Fleischhacker, M., Gahan, P. B., Hui, L., Holdenrieder, S., & Thierry, A. R. (2020) · Human Genetics · doi:10.1007/s00439-020-02227-2 · Cited by 74
Clonal Hematopoiesis and Blood-Cancer Risk
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1500684 · Cited by 68
Self-citationBone marrow niche in the myelodysplastic syndromes
Cogle, C. R., Saki, N., Khodadi, E., Li, J., Shahjahani, M., & Azizidoost, S. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.06.017 · Cited by 73
Cortés-López, M., Chamely, P., Hawkins, A. G., Stanley, R. F., Swett, A. D., Ganesan, S., Mouhieddine, T. H., Dai, X., Kluegel, L., Chen, C. Y., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.07.012 · Cited by 69
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Wan, J. C. M., Sasieni, P. D., & Rosenfeld, N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01033-x · Cited by 82
“Even with error suppression, clonal haematopoiesis of indeterminate potential (CHIP), which is a universal mechanism of ageing in which mutations accumulate in blood cells or bone marrow cells 43,60,61 , presents an additional challenge.”
for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG), Gaidzik, V. I., Weber, D., Paschka, P., Kaumanns, A., Krieger, S., Corbacioglu, A., Krönke, J., Kapp‐Schwoerer, S., Kraemer, D. M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.200 · Cited by 74
Baumgartner, J. M., Raymond, V. M., Lanman, R. B., Tran, L., Kelly, K. J., Lowy, A. M., & Kurzrock, R. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6561-z · Cited by 74
“DNA in the circulation may also come from sources other than the tumor in question, such as a second primary or myeloid premalignant condition known as clonal hematopoiesis of indeterminate origin.(34) Other limitations of ctDNA, as it becomes more sensitive, may theoretically include the ability to discern genomic mu…”
Nagata, Y., Makishima, H., Kerr, C. M., Przychodzen, B. P., Aly, M. M., Goyal, A., Awada, H. K., Asad, M., Kuzmanovic, T., Suzuki, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13001-y · Cited by 71
Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
Zarka, J. G., Short, N. J., Kanagal‐Shamanna, R., & Issa, G. C. (2020) · Genes · doi:10.3390/genes11060649 · Cited by 77
Alterations to DNMT3A in Hematologic Malignancies
Venugopal, K., Feng, Y., Shabashvili, D. E., & Guryanova, O. A. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3033 · Cited by 76
Tong, J., Sun, T., Ma, S., Zhao, Y., Ju, M., Gao, Y., Zhu, P., Tan, P., Fu, R., Zhang, A., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.01.018 · Cited by 62
Bick, A. G., Popadin, K., Thorball, C. W., Uddin, M. M., Zanni, M. V., Yu, B., Cavassini, M., Rauch, A., Tarr, P., Schmid, P., et al. (2022) · Scientific Reports · doi:10.1038/s41598-021-04308-2 · Cited by 73
Rando, T. A., Brunet, A., & Goodell, M. A. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.06.004 · Cited by 80
“Accordingly, the risk of developing hematologic malignancies is increased in the context of CH. 68,113 Importantly, CH is also associated with an elevated risk for some non-hematologic conditions, particularly cardiovascular disease.”
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells
Reinisch, A., Chan, S. M., Thomas, D., & Majeti, R. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.03.008 · Cited by 73
“Recently, the existence of clonal hematopoiesis carrying the same mutations was confirmed in two large cohort studies performed in elderly individuals with no hematologic malignancies.(25,26)”
Perdomo, S. P., Avogbe, P. H., Foll, M., Abedi‐Ardekani, B., Facciolla, V. L., Anantharaman, D., Chopard, P., Calvez‐Kelm, F. L., Vilensky, M., Polesel, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20004 · Cited by 75
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
Valent, P., Kern, W., Hoermann, G., Feenstra, J. D. M., Sotlar, K., Pfeilstöcker, M., Germing, U., Sperr, W. R., Reiter, A., Wolf, D. G. F., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030789 · Cited by 74
Zhang, X., Zhao, W., Wei, W., You, Z., Ou, X., Sun, M., Yin, Y., Tang, X., Zhao, Z., Hu, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4055 · Cited by 71
“ctDNA testing can incidentally detect somatic mutations related to clonal hematopoiesis in elder people (13, 17) as well as somatic mutations in people without a confirmed cancer diagnosis (18).”
BackgroundClonal hematopoiesis in the inherited bone marrow failure syndromes
Tsai, F. D., & Lindsley, R. C. (2020) · Blood · doi:10.1182/blood.2019000990 · Cited by 65
Preleukemia: one name, many meanings
Koeffler, H. P., & Leong, G. X. Y. (2016) · Leukemia · doi:10.1038/leu.2016.364 · Cited by 74
Evolving Significance of Tumor-Normal Sequencing in Cancer Care
Mandelker, D. L., & Ceyhan‐Birsoy, O. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.11.006 · Cited by 74
Clonal Hematopoiesis: A New Step Linking Inflammation to Heart Failure
Yura, Y., Sano, S., & Walsh, K. X. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.08.006 · Cited by 76
“, in the absence of overt changes in erythrocytes, platelets, or leukocytes) (40,46,56).”
BackgroundInfluentialShared genetic and epigenetic changes link aging and cancer
Zabransky, D. J., Jaffee, E. M., & Weeraratna, A. T. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.01.004 · Cited by 72
Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis
Zhou, X., Cheng, Z., Dong, M., Liu, Q., Yang, W., Liu, M., Tian, J., & Cheng, W. (2022) · Nature Communications · doi:10.1038/s41467-022-35320-3 · Cited by 73
Brambati, C., Galbiati, S., Xue, E., Toffalori, C., Crucitti, L., Greco, R., Sala, E., Crippa, A., Chiesa, L., Soriani, N., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.135467 · Cited by 73
“However, it should also be considered that these mutations are not specific hallmarks of transformed cells, and have frequently been detected in the peripheral blood (PB) of healthy individuals where they are considered to represent pre-leukemic alterations, acting as a fertile soil for subsequent development of hemat…”
BackgroundLiquid biopsy for the identification of intravascular large B-cell lymphoma
Suehara, Y., Sakata‐Yanagimoto, M., Hattori, K., Nanmoku, T., Itoh, T., Kaji, D., Yamamoto, G., Abe, Y., Narita, K., Takeuchi, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.178830 · Cited by 71
“However, this is unlikely because, in a large-scale study, L265P MYD88 and Y196 CD79B were found only in 1/12380 and 0/12380 with the cut-off value of 2%.(15) Because our sequencing analysis was not comprehensive, it is possible that more suitable for mutational analysis could be found.”
BackgroundLink-Lenczowska, D., Pallisgaard, N., Cordua, S., Zawada, M., Czekalska, S., Krochmalczyk, D., Kanduła, Z., & Sacha, T. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3451-1 · Cited by 68
Genetic landscape of adult Langerhans cell histiocytosis with lung involvement
Jouenne, F., Chevret, S., Bugnet, E., Clappier, E., Lorillon, G., Meignin, V., Sadoux, A., Cohen, S., Haziot, A., How‐Kit, A., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01190-2019 · Cited by 69
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Jager, M., Blokzijl, F., Sasselli, V., Boymans, S., Janssen, R., Besselink, N., Clevers, H., van Boxtel, R., & Cuppen, E. (2018) · Nature Protocols · doi:10.1038/nprot.2017.111 · Cited by 66
Wouters, H. J. C. M., Mulder, R., van Zeventer, I. A., Schuringa, J. J., van der Klauw, M. M., van der Harst, P., Diepstra, A., Mulder, A. B., & Huls, G. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003323 · Cited by 74
“The most commonly mutated genes in CHIP include DNMT3A, TET2, and ASXL1.(10,14,15) CHIP confers a 0.”
BackgroundResultInfluentialClonal hematopoiesis in sickle cell disease
Pincez, T., Lee, S. S. K., Ilboudo, Y., Preuss, M., Pham Hung d’Alexandry d’Orengiani, A.-L., Bartolucci, P., Galactéros, F., Joly, P., Bauer, D. E., Loos, R. J. F., et al. (2021) · Blood · doi:10.1182/blood.2021011121 · Cited by 66
Rahmani, N. E., Ramachandra, N., Sahu, S., Gitego, N., López, A., Pradhan, K., Bhagat, T. D., Gordon-Mitchell, S., Rivera-Peña, B., Kazemi, M., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00541-0 · Cited by 74
Clonal Hematopoiesis and Its Impact on Human Health
Ahmad, H., Jahn, N., & Jaiswal, S. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-112347 · Cited by 66
Ainciburu, M., Ezponda, T., Berastegui, N., Alfonso-Pierola, A., Vilas-Zornoza, A., San Martin-Uriz, P., Alignani, D., Lamo-Espinosa, J., San-Julian, M., Jiménez-Solas, T., et al. (2023) · eLife · doi:10.7554/elife.79363 · Cited by 66
JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism
Zon, R. L., Sekar, A., Clapham, K. R., Oren, O., Niroula, A., Bick, A. G., Gibson, C. J., Griffin, G. K., Uddin, M. M., Neuberg, D. S., et al. (2024) · Blood · doi:10.1182/blood.2024024187 · Cited by 75
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.